2-Arachidonoylglycerol (2-AG)
/ar-uh-KID-oh-noh-il-GLIS-er-ol/
The most abundant endocannabinoid in the brain. A full agonist at both CB1 and CB2 receptors.
In Depth
2-AG is present at concentrations 170-fold higher than anandamide in the brain. It is synthesized from diacylglycerol (DAG) by diacylglycerol lipase (DAGL) and degraded primarily by monoacylglycerol lipase (MAGL). 2-AG is the primary endogenous ligand for CB2 receptors and plays a major role in retrograde synaptic signaling, neuroinflammation, and neuroprotection.
Related Terms
More in Pharmacology
Endocannabinoid System (ECS)
A lipid-based retrograde neurotransmitter system comprising endogenous cannabinoids (endocannabinoids), their receptors (CB1, CB2), and metabolic enzymes.
CB1 Receptor
Cannabinoid receptor type 1. A G protein-coupled receptor (GPCR) primarily expressed in the central nervous system. The primary target of THC's psychoactive effects.
CB2 Receptor
Cannabinoid receptor type 2. A GPCR primarily expressed in immune tissues and peripheral organs. Less abundant in the CNS than CB1.
Anandamide (AEA)
N-arachidonoylethanolamine. The first endocannabinoid identified. A partial agonist at CB1 and CB2 receptors, named from the Sanskrit word "ananda" meaning bliss.
FAAH (Fatty Acid Amide Hydrolase)
The primary enzyme responsible for degrading anandamide and other fatty acid amides. A key target for increasing endocannabinoid tone.